Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 18/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.62 |
| ▸ | ABL1 | P00519 | 16/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.62 |
| ▸ | PRKDC | P78527 | 16/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.62 |
| ▸ | EGFR | P00533 | 15/20 | 0.62 |
| ▸ | KDR | P35968 | 15/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.62 |
| ▸ | HCK | P08631 | 14/20 | 0.62 |
| ▸ | MTOR | P42345 | 14/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 14/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15978893 | 0.91 | RET (0.62) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL14985435 | 0.89 | RET (0.73) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL12120525 | 0.88 | RET (0.67) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL15978894 | 0.87 | RET (0.67) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL15978895 | 0.85 | RET (0.68) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL14985436 | 0.84 | RET (0.85) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL14985441 | 0.84 | RET (0.67) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL5804211 | 0.84 | AURKB (0.59) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL14985447 | 0.84 | RET (0.61) | RETSRCPIK3CDABL1PIK3CA | |
| SCHEMBL5823907 | 0.83 | AURKA (0.58) | RETSRCPIK3CDABL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-9895373-B2 | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895373-B2 | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160354377-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-12-08 | — | — | US | disclosed |
| US-20160354377-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-12-08 | — | — | US | disclosed |
| US-9321772-B2 | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321772-B2 | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140243357-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243357-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013077921-A9 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013077921-A2 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | RET 1104/4885SRC 2138/4885PIK3CD 1835/4885 |
| US-20160354377-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | DPYD, TYMP, TYMS | RET 813/4885SRC 1163/4885PIK3CD 1226/4885 |
| US-20140243357-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AND USES THEREOF | DPYD, TYMP, TYMS | RET 813/4885SRC 1163/4885PIK3CD 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.